Silence Therapeutics plc

Silence Therapeutics plc is a biotechnology company focused on discovering and developing siRNA-based medicines that silence disease-associated genes through RNA interference. The company is headquartered in London, operates as a UK public limited company, and has its ADSs listed on Nasdaq in the United States.

−16 237,0 %

61,5 %

−15 851,9 %

−98,7 %

8.72

8.72

— Silence Therapeutics plc
%
siRNA therapeutics platform70% Discovery and development of short interfering RNA molecules designed to silence specific genes.
Collaboration licenses and options30% Out-licensing of RNAi targets and programs to pharmaceutical partners under collaboration agreements.

Silence Therapeutics primarily sells to large pharmaceutical partners through collaboration and licensing agreements...

  • Pharmaceutical collaboration partnersprimary

    License RNAi targets and programs to advance internal pipelines and share development rights.

  • Biotech development partnersprimary

    Partner on specific targets or programs where Silence contributes platform technology and discovery capability.

  • Future physicians and specialty clinicsemerging

    Would prescribe approved therapies in rare or specialty disease settings if products reach market.

  • Patients and caregiversemerging

    End users of any approved RNAi medicines, especially in diseases with limited treatment options.

  • Payers and reimbursement authoritiesemerging

    Determine coverage and reimbursement for any commercialized therapies, affecting adoption.

Silence Therapeutics is based in London and maintains a corporate presence in the United Kingdom, with additional...

  • •Headquartered in London, United Kingdom
  • •Berlin office supports research and operating activities
  • •United States is a key corporate and capital markets base
  • •Collaboration rights can be worldwide or region-specific
  • •Greater China is relevant through the Hansoh agreement

Silence Therapeutics is focused on advancing its siRNA platform into partnered and proprietary programs aimed at...

01
Grow the RNAi pipelinemedium-term

A broader pipeline increases partnering opportunities and future product optionality.

02
Secure and expand collaborationsshort-term

Partner funding helps offset development costs and validates target selection.

03
Advance clinical-stage programsmedium-term

Clinical progress is required to create value and support future approvals.

04
Prepare for future commercializationlong-term

Approved products would require sales, distribution, reimbursement, and manufacturing capabilities.

The company faces the typical risks of a clinical-stage biotech: development failure, regulatory delays, and dependence...

high

Pipeline and clinical development failure

The business depends on proving that siRNA candidates are safe and effective in humans.

Scope
Clinical-stage programs
Materiality
high
high

Partner concentration and collaboration dependence

A significant portion of revenue comes from collaboration agreements and milestones.

Scope
AstraZeneca, Mallinckrodt, Hansoh
Materiality
high
medium

Reimbursement and market access risk

Even approved RNAi therapies may face payer resistance or pricing pressure.

Scope
Future commercial products
Materiality
high
medium

Manufacturing and supply chain constraints

The company does not own manufacturing facilities and relies on cGMP contractors.

Scope
Clinical and commercial supply
Materiality
high
medium

Data privacy and security compliance

Failure to comply with evolving privacy laws can lead to investigations, fines, and disruption.

Scope
U.S. and foreign operations
Materiality
medium
Revenue recognition under collaboration agreements
Affects quarterly revenue volatility and comparability
Clinical and manufacturing commitments
Affects expense recognition and cash planning
Foreign currency translation and transaction gains/losses
Can materially affect reported earnings and cash flow
Valuation of short-term investments
Affects other income and liquidity presentation

Rani Therapeutics Holdings, Inc.

RANI · Pharmaceutical Preparations

Silexion Therapeutics Corp

SLXN · Biological Products, (No Diagnostic Substances)

Oncotelic Therapeutics, Inc.

OTLC · Pharmaceutical Preparations

Pasithea Therapeutics Corp.

KTTAW · Pharmaceutical Preparations

Vir Biotechnology, Inc.

VIR · Biological Products, (No Diagnostic Substances)

Royalty Pharma plc

RPRX · Pharmaceutical Preparations

: 29/04/2026